Fresenius Medical Care Looks Cheap After the CEO Change - but Is the Market Right to Stay Skeptical?

The valuation gap: weak sentiment versus stronger operating results

The market is still treating Fresenius Medical Care like a company in repair mode. After the latest quarter, that gap looks harder to justify. The stock has fallen 23.13% over the past year, even though the company just reported organic revenue growth of 5%, operating income growth of 23%, and EPS increases of 28%. The question now is whether investors should keep focusing on the recent drawdown or start valuing the recovery more directly.

Why sentiment has lagged the business

This looks like a classic case of loss aversion: once a stock starts slipping, investors tend to hold onto bad news longer than the fundamentals deserve. That makes recent weakness harder to shake, even when the latest results improve.

Management still had to work through that psychology. In the first quarter, reported results were weighed down by FME25+ transformation program related one-time costs, which helped explain why reported operating income declined 14% and reported net income fell 22%. The broader point was to look past accounting noise and focus on underlying execution. Six weeks later, the follow-through mattered.

Why the buyback matters

The buyback is more than a capital-return headline. It suggests management sees enough financial strength to press ahead despite the transformation. A second tranche of around EUR 415 million ran from January 12 to May 8, 2026, and because the first tranche finished early, the total EUR 1 billion share buyback program is expected to be completed in less than a year, significantly ahead of schedule.

That does not eliminate risk, but it does argue that the near-term case is stronger than the stock sentiment implies.

FME25+ costs have clouded the picture, but the operating trend has improved

The real debate is whether FME25+ is still distorting the income statement, or whether the market is treating temporary disruption as lasting damage.

Reported weakness was heavily affected by one-time costs

In the first quarter, the headline numbers looked worse than the underlying business. Reported operating income declined 14% and reported net income decreased 22%, mainly because of FME25+ transformation program related one-time costs. The key point is that the reported decline does not tell the whole story on its own. Investors can easily anchor to the reported drop and read it as evidence of a weakening core business, even though the disruption costs were being absorbed upfront.

The next quarter showed better follow-through

Six weeks later, the trend did not weaken. The latest quarter delivered organic revenue growth of 5%, operating income growth of 23%, and EPS growth of 28%. That is not usually what a deteriorating core business looks like. It suggests the market may have given too much weight to the ugly reported numbers in the first quarter and not enough weight to the fact that growth and profitability both improved afterward.

The 5008X rollout adds operational support to the story

The clearest support is operational rather than narrative. The 5008X CAREsystem rollout has reached 227 U.S. clinics and delivered more than 600,000 treatments. At that scale, this is no longer just a pilot story. It shows the company is still advancing innovation while the existing business keeps expanding.

When the market's caution would be justified

The market would be right to stay more cautious if U.S. dialysis headwinds deepen or if launch investments and other costs stay elevated long enough to outweigh rate improvements and revenue-cycle gains. Bears can point to weak US treatment growth and argue that new-product launch investment may weigh on near-term margins. If those pressures build, the current discount may be rational. Absent that, anchoring to disruption costs risks mistaking a transition bill for a structural problem.

Helen Giza's mandate is about execution credibility, not headline optics

The CEO change is the visible event, but the multiple will move mainly on credibility. Helen Giza is not an outsider dropped into a repair job; she joined Fresenius Medical Care in 2019, became Chief Executive Officer effective December 6, 2022, and then served as acting Chief Financial Officer until September 30, 2023. That mix of strategy, finance, and transformation experience matters more than the headline change. Investors are not paying for a new name on the door. They are deciding whether the current team deserves renewed trust on capital allocation.

The recent appointment of Charles Hugh-Jones as Global Chief Medical Officer strengthens the broader leadership narrative, but the harder test remains execution. The key question is whether management can keep protecting cash returns and continue delivering another quarter of highly profitable growth while the operating model improves.

Why the buyback changes the math

Accelerated repurchases matter because they can support EPS even if the market stays skeptical for longer. The first tranche was completed ahead of schedule on December 29, 2025, and a second tranche of around EUR 415 million followed earlier this year. That suggests management believes cash generation can support the program without weakening the transition. It also helps explain part of the EPS growth reported in the latest quarter.

Where the valuation debate actually sits

Valuation views remain spread out. One fair-value story implies the stock is 13.6% undervalued, while another places it 39% below fair value. That range shows the real disagreement is not whether Fresenius has value drivers. It is how much fear the market is still reflecting in the price.

What would keep the case intact - and what could break it

Supports the bullish case: - The company has continued to defend a growth and profitability narrative. - The buyback has remained active, with a second tranche of around EUR 415 million. - Management says execution against the FME Reignite strategy is still on track.

Weakens the case: - Weak US treatment growth persists. - Investments tied to new product launches pressure margins for longer than expected. - The buyback slows before the broader capital-return program is complete.